hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06281574, orgStudyIdInfo id: S67346, briefTitle: What Are the Determinants for RTW After SA, acronym: RTW after SA, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-13, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Universitaire Ziekenhuizen KU Leuven, class: OTHER, descriptionModule briefSummary: Shoulder arthroplasty is becoming increasingly common, due to ageing of the population. Historically, surgeons have been reluctant to use a shoulder replacement in younger patients. During the last decades however, there was an improvement of surgical techniques and implants which resulted in the fact that these procedures are nowadays more frequently used in younger patients. Combined with the increasing life expectancy and the increased age of retirement, both elderly and younger patients hope to continue their jobs after prosthetic replacement.Recent literature shows that the majority patients is able to resume their work following shoulder arthroplasty.This study aims to analyze the RTW percentage in a Belgian cohort of patients with a shoulder replacement. This study hopes to identify factors that might influence the RTW., conditionsModule conditions: Shoulder Arthroplasty, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaires, outcomesModule primaryOutcomes measure: Return to work, secondaryOutcomes measure: Type of shoulder arthroplasty, secondaryOutcomes measure: WORQ-UP (work-related questionnaire for upper extremity disorders), secondaryOutcomes measure: SSV (Subjective Shoulder Value), secondaryOutcomes measure: SST (Dutch translation of the Simple Shoulder Test), secondaryOutcomes measure: OSS (Oxford Shoulder Score), secondaryOutcomes measure: Self-made questionnaire, secondaryOutcomes measure: Belgisch Kenniscentrum over welzijn op het werk (BeSWIC), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 63 Years, stdAges: ADULT, contactsLocationsModule locations facility: UZ Leuven, city: Leuven, state: Vlaams-Brabant, zip: 3000, country: Belgium, geoPoint lat: 50.87959, lon: 4.70093, hasResults: False
protocolSection identificationModule nctId: NCT06281561, orgStudyIdInfo id: FirstAHXiamenU-YB, briefTitle: Dexmedetomidine Premedication for Post-anaesthesia Sleep Disturbance, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Xiamen University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn about the effect of preoperative nasal spry with dexmedetomidine on postoperative sleep disturbance in young to middle-aged women undergoing hysteroscopy. The main questions it aims to answer are:1) what is the incidence of postoperative sleep disturbance in unisex patients who receive propofol anesthesia. 2) The preventive effect of preanesthesia nasal spray dexmedetomidine on postoperative sleep disturbance.Participants will receive total intravenous propofol anaesthesia after dexmedetomidine nasal spray. Sleep quality will be monitored by using a Wearable devices and the PSQI which was used to assess sleep quality 1,2 days before the surgery and 1,3,7 days after surgery.Researchers will compare the effects of 0.2 or 0.5 ug/kg dexmedetomidine to see if it help improve postanesthesia sleep quality., conditionsModule conditions: Postoperative Sleep Disturbance, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: Normal Saline, interventions name: Dexmedetomidine, outcomesModule primaryOutcomes measure: Change from baseline sleep quality at after intervention, primaryOutcomes measure: Pittsburgh sleep quality index(PSQI), secondaryOutcomes measure: Early recovery evaluated by Aldrete rating scale, secondaryOutcomes measure: Later Recovery evaluated by QoR-40 questionnaire, eligibilityModule sex: FEMALE, minimumAge: 23 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06281535, orgStudyIdInfo id: 21789, briefTitle: Early Versus Conventional Loading for Fully Guided Immediate Implant Placement, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-06-15, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, collaborators name: Assiut University, descriptionModule briefSummary: Conventional loading protocol following implant placement 3 -6 months is considered the gold standard. However, early loading following 2 months after implant placement decreases the time and had a good survival rate., conditionsModule conditions: Dental Implant, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Implant loading, outcomesModule primaryOutcomes measure: Implant stability, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06281522, orgStudyIdInfo id: University of Health Sciences, briefTitle: The Importance of Inflammatory Markers Calculated From Preoperative and Postoperative Peripheral Blood Results in the Diagnosis and Treatment of Patients Operated for Hydatid Cyst of the Lung (Lung Echinococcus Granulosus), acronym: Echinococcusis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-18, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Abdullah Adiyaman, class: OTHER, descriptionModule briefSummary: This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice., conditionsModule conditions: Lung Hydatid Cyst, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Operated patients with hydatid cyst of the lung, outcomesModule primaryOutcomes measure: Calculation of laboratory markers, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 83 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Health Sciences, Van Training and Research Hospital, status: RECRUITING, city: Van, country: Turkey, geoPoint lat: 38.49457, lon: 43.38323, hasResults: False
protocolSection identificationModule nctId: NCT06281509, orgStudyIdInfo id: S68374, briefTitle: Palmaris Longus Muscle and Dupuytren, acronym: Palmaris, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-16, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Universitaire Ziekenhuizen KU Leuven, class: OTHER, descriptionModule briefSummary: Dupuytren disease is a medical condition characterized by the painless formation of nodules in the palm of the hand. Cords are formed on the palmar fascia, a connective tissue sheet in the palm of the hand. This fascia is seen as the vestigial remnant of the palmaris longus tendon. The PLM attaches to the fascia palmaris. A muscle that not everyone has and can therefore be clearly missed. This raises the question of whether the presence of the musculus palmaris longus has any association with the development, recurrence and/or progression of DD and contractures. To investigate a potential predisposition, this study intend to assess the prevalence of the PLM in a group of individuals affected by DD and compare it with a control group (age matched, no signs of DD) without the condition., conditionsModule conditions: Dupuytren's Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two groups: Patients with Dupuytren Disease and healthy control group. They will be age matched (50 years of age or higher) with the objective to have a proportionate division (50/50) between the genders., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, maskingDescription: No masking will be done in this study, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands., interventions name: Ultrasound, outcomesModule primaryOutcomes measure: PLM in the DD versus control, primaryOutcomes measure: PML in mild versus severe DD-group, secondaryOutcomes measure: PLM presence in DD affected group, secondaryOutcomes measure: PLM presence in control group, secondaryOutcomes measure: Dominant versus non-dominant hand, secondaryOutcomes measure: Male versus female population, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitaire Ziekenhuizen KU Leuven, status: RECRUITING, city: Leuven, state: Vlaams-Brabant, zip: 3000, country: Belgium, contacts name: Ilse Degreef, Prof. Dr., role: CONTACT, phone: +32 16 33 88 43, email: ilse.degreef@uzleuven.be, contacts name: Anna Tarasiuk, role: CONTACT, phone: +32 16 33 88 18, email: orthopedie.research@uzleuven.be, geoPoint lat: 50.87959, lon: 4.70093, hasResults: False
protocolSection identificationModule nctId: NCT06281496, orgStudyIdInfo id: Rigshospitalet, Hematology, briefTitle: AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation, acronym: AlloCare, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-10-01, completionDateStruct date: 2026-12-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Rigshospitalet, Denmark, class: OTHER, collaborators name: Danish Cancer Society, descriptionModule briefSummary: A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase., conditionsModule conditions: Hematological Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: One site, two arm randomized controlled trial, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: AlloCare, outcomesModule primaryOutcomes measure: EORTC Quality of Life Survivorship Core questionnaire (EORTC-QOL-SURV100), secondaryOutcomes measure: Modified 7-day Lee Chronic-versus-Host Disease Symptom Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rigshospitalet, city: Copenhagen, zip: 2100, country: Denmark, contacts name: Mette Schaufuss Engedal, MSc, role: CONTACT, phone: +45 51896699, email: mette.schaufuss.engedal@regionh.dk, contacts name: Mary Jarden, Professor, role: CONTACT, email: mary.jarden@regionh.dk, geoPoint lat: 55.67594, lon: 12.56553, hasResults: False
protocolSection identificationModule nctId: NCT06281483, orgStudyIdInfo id: APCs in chronic skin ulcers, briefTitle: PRP Versus PRF Versus Conventional Treatment in Chronic Non-healing Skin Ulcers, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Kafrelsheikh University, class: OTHER, collaborators name: Helwan University, descriptionModule briefSummary: To compare the therapeutic efficacy of PRP and PRF: two relatively newer modalities in the management of chronic non-healing ulcers versus conventional treatment., conditionsModule conditions: Chronic Non-healing Skin Ulcers, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: platelet-rich plasma, interventions name: platelet-rich fibrin, interventions name: Surgical debridement, normal saline washing and dressing coverage, outcomesModule primaryOutcomes measure: Objective assessment of ulcer size for effectiveness, using Image J software., primaryOutcomes measure: Pain assessment, primaryOutcomes measure: Any adverse effects related to treatment modality, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Badr Hospital - Helwan University and Kafrelseikh University Hospital, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Mohamed Aboshabana Hussein, Assistant Lecturer, role: CONTACT, phone: 01007981008, email: dr.mohamedaboshabana@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06281470, orgStudyIdInfo id: WS016-Ⅰ-01, briefTitle: The Safety and Tolerability of WS016 in Healthy Chinese Volunteers, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-13, primaryCompletionDateStruct date: 2023-06-15, completionDateStruct date: 2023-06-15, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Waterstone Pharmaceutical (Wuhan) Co., LTD., class: INDUSTRY, descriptionModule briefSummary: This clinic trial evaluates the safety and tolerability of single- and multiple- ascending doses of WS016 in healthy adult participants. There will be about 64 participants,48 active and 16 placebo., conditionsModule conditions: Hyperkalemia, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 66, type: ACTUAL, armsInterventionsModule interventions name: WS016 Single Dose(6g), interventions name: WS016 Single Dose(12g), interventions name: WS016 Single Dose(24g), interventions name: WS016 Single Dose(36g), interventions name: WS016 Single Dose(48g), interventions name: SAD matching placebo, interventions name: WS016 Multiple Dose(12g), interventions name: WS016 Multiple Dose(24g), interventions name: WS016 Multiple Dose(48g), interventions name: MAD matching placebo, outcomesModule primaryOutcomes measure: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single- and multiple- ascending dose, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Zhejiang Xiaoshan Hospital, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06281431, orgStudyIdInfo id: CPSP, briefTitle: A Comparative Effect of Echogenic Needle for Nerve Block on Acute and Chronic Postoperative Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-12, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: The Second Affiliated Hospital of Chongqing Medical University, class: OTHER, descriptionModule briefSummary: Surgical pain is a common complication after surgery, affecting patient recovery and treatment quality. \>20% of patients suffer from chronic postoperative pain. China has \>70 million surgeries yearly. Nerve block manages postoperative pain, with developing nerve block needles now used in clinics. Developed needles may have better pain management effects than non-developed ones, but their effect on reducing chronic pain remains unclear. This study aims to explore the effect of developed nerve block needles on postoperative pain and compare them to non-developed needles, providing new ideas and methods for pain management., conditionsModule conditions: Chronic Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Echogenic nerve block needle, interventions name: Non-echogenic nerve block needle, outcomesModule primaryOutcomes measure: Chronic postoperative pain, primaryOutcomes measure: Moderate to severe pain, secondaryOutcomes measure: Acute postoperative pain, secondaryOutcomes measure: Acute postoperative pain, secondaryOutcomes measure: Acute postoperative pain, secondaryOutcomes measure: Puncture operation time, secondaryOutcomes measure: Number of needle passes, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: He Huang, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 4000000, country: China, contacts name: He Huang, ph.D, role: CONTACT, phone: 13708385559, email: huanghe@cqmu.edu.cn, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06281418, orgStudyIdInfo id: 5-24, briefTitle: Postoperative Intraperitoneal Pain Management Following Laparoscopic Cholecystectomy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Future University in Egypt, class: OTHER, descriptionModule briefSummary: Postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. No. study has investigated IP granisetron as an adjuvant to standard care for postoperative pain management in patients undergoing LC., conditionsModule conditions: Post Operative Pain, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Granisetron 1 Mg/mL Intravenous Solution, interventions name: Normal saline, outcomesModule primaryOutcomes measure: VAS score, secondaryOutcomes measure: Time to analgesic request, secondaryOutcomes measure: Quality of life (QoL) after laparoscopic cholecystectomy (LC), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Hepatology and Tropical Research Institute, status: RECRUITING, city: Cairo, zip: 11617, country: Egypt, contacts name: Hoda Mohamed Bayoumi, Bachelor's, role: CONTACT, phone: 01126143971, email: hoda.bayoumy@fue.edu.eg, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06281405, orgStudyIdInfo id: FDRT-2023-290-3409, briefTitle: CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer, acronym: TORCH-iTNT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined with CAPOX (ToriCAPOX). Group B receives SCRT (25Gy/5Fx) followed by 6 cycles of ToriCAPOX. TME surgery is scheduled after TNT while a watch and wait (W\&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response \[pCR\] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, anal preservation rate, 3-year DFS rate, etc., conditionsModule conditions: Locally Advanced Rectal Cancer, conditions: Neoadjuvant Therapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 198, type: ESTIMATED, armsInterventionsModule interventions name: PD-1 antibody, interventions name: Capecitabine, interventions name: Short-course radiotherapy, outcomesModule primaryOutcomes measure: Complete response (CR) rate, secondaryOutcomes measure: Grade 3-4 adverse effects rate, secondaryOutcomes measure: 3 year anal preservation rate, secondaryOutcomes measure: 3 year disease free survival rate, secondaryOutcomes measure: 3 year local recurrence free survival rate, secondaryOutcomes measure: 3 year overall survival rate, secondaryOutcomes measure: Rate of surgical complications, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, city: Shanghai, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False